Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Glaucoma
Interventions: Rocklatan eye drops will be instilled nightly in one eye diagnosed with glaucoma for up to 12 months., Two optical coherence tomography (OCT) devices will be used to assess blood flow changes.; Drug · Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: HIV Infections
Interventions: Vitamin D supplement, Placebo; Dietary Supplement · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 24 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more

Conditions: Tooth Loss
Interventions: Control Collagen Wound Dressing, Test Collagen Matrix; Device
Lead sponsor: McGuire Institute; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Fenton, Michigan

Conditions: Heart Failure, Acute Heart Failure
Interventions: Protocolized diuretic therapy; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 19 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, sitagliptin, metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 60
States / cities: Birmingham, Alabama • Escondido, California • Fresno, California + 54 more

Conditions: Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions: Posoleucel (ALVR105), Placebo; Biological
Lead sponsor: AlloVir; Industry
Eligibility: Not listed
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 31 more

Conditions: Tuberculosis
Interventions: Moxifloxacin, PA-824, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma
Interventions: HPV vaccine, Imiquimod, and metformin combination therapy; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Dementia
Interventions: Not listed
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 50 Years to 81 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Diabetes Mellitus, Type 2
Interventions: Linagliptin, Empagliflozin + Linagliptin, Empagliflozin placebo + Linagliptin placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 28
States / cities: Gulf Shores, Alabama • Norwalk, California • San Diego, California + 24 more

Conditions: Caries, Metabolomic Profile
Interventions: Drinking water, Apple juice; Other
Lead sponsor: Jodi Stookey; Government
Eligibility: 5 Years to 10 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Ankylosing Spondylitis
Interventions: Secukinumab, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 25
States / cities: Irvine, California • La Mesa, California • San Leandro, California + 22 more

Conditions: Actinic Keratoses
Interventions: imiquimod cream, 3.75%, Vehicle Cream; Drug
Lead sponsor: Actavis Mid-Atlantic LLC; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 19
States / cities: Birmingham, Alabama • Miami, Florida • Newnan, Georgia + 16 more

Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Olaparib, Placebo, Abiraterone, Prednisone or prednisolone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Male only
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 2
States / cities: San Diego, California • Lake Success, New York

Conditions: Hypertension
Interventions: Audit and Feedback, Pharmacist E-Detailing; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 79 Years
Enrollment: 511 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes
Interventions: Cagrilintide, Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 21
States / cities: Huntington Park, California • Northridge, California • Santa Ana, California + 18 more

Conditions: Actinic Keratosis (AK)
Interventions: RLS-1496 1.0% cream; Drug
Lead sponsor: Rubedo Life Sciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 4
States / cities: Hot Springs, Arkansas • New Brighton, Minnesota • Omaha, Nebraska + 1 more

Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Familial Hypercholesterolemia
Interventions: Child(ren) receive an adult-onset result, Child(ren) received a pediatric-onset result, Control - Negative Result, Adolescents who received adult-onset result, Adolescents who received a pediatric-onset result, Adolescent controls - negative for familial variant; Genetic
Lead sponsor: Geisinger Clinic; Other
Eligibility: Not listed
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Periodontal Diseases
Interventions: Connective Tissue Graft Technique, Pinhole Surgical Technique; Procedure
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 19 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Laxity; Skin
Interventions: Ultherapy Prime; Device
Lead sponsor: The Levine Center for Plastic Surgery; Other
Eligibility: 25 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Pain, Opioid Use, Lumbar Disc Herniation
Interventions: Ropivacaine injection Location 1, Ropivacaine injection Location 2, Multimodal Pharmacological Management; Drug
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 40 Years to 80 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Surgical Site Infection
Interventions: ChloraPrep, 0.1% Sodium Lauryl Sulfate, 0.9% Physiological Saline, ZuraPrep without IPA; Drug · Other
Lead sponsor: Zurex Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Noise Exposure, Noise-induced Hearing Loss, Noise; Adverse Effect, Mild Therapeutic Hypothermia, Cooling, Occupational Exposure, Occupational Health, Hidden Hearing Loss
Interventions: Cold pack-delivered mild therapeutic hypothermia; Device
Lead sponsor: Restorear Devices LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Herpes Zoster, Postherpetic Neuralgia
Interventions: ARYS-01 (sorivudine) cream 3% or placebo cream, placebo, valaciclovir; Drug
Lead sponsor: aRigen Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 10
States / cities: Beverly Hills, California • Encino, California • Vista, California + 5 more

Search by objective public record fields.

Rocklatan Retinal Perfusion OCT Study

Vitamin D Reabsorption in Adolescents and Young Adults With HIV Infection

A Comparison of Two Socket Sealing Collagen Matrices for Extraction Socket Management

Randomized Controlled Trial of urinE chemiStry Guided aCute heArt faiLure treATmEnt (ESCALATE)

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers

HPV Vaccine, Imiquimod, and Metformin Combination Trial

A Study to Compare Genetic Variations of IGF-I and IGF-II

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Saliva Insulin as Biomarker of Risk Factors for Metabolic Dysregulation and Caries

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Personalizing Intervention to Reduce Clinical Inertia in the Treatment of Hypertension

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise

Evaluate RLS-1496 Topical Cream for Actinic Keratosis

Pediatric Reporting of Adult-Onset Genomic Results

Pinhole Surgical Technique Compared to Connective Tissue Graft in Treatment of Gingival Recession

Long-Term Efficacy and Duration of MFU-V at Multiple Depths and at 1.5 mm

Comparison of Quadratus Lumborum Block Types

Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA

Non-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)